Kohn EC - Search Results

1

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Azad NS, et al. Among authors: kohn ec. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. J Clin Oncol. 2008. PMID: 18669456 Free PMC article. Clinical Trial.

2

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E. Sarosy G, et al. J Clin Oncol. 1992 Jul;10(7):1165-70. doi: 10.1200/JCO.1992.10.7.1165. J Clin Oncol. 1992. PMID: 1376773 Clinical Trial.

3

Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.

Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA, Ihde DC. Kohn EC, et al. J Clin Oncol. 1990 Jan;8(1):155-60. doi: 10.1200/JCO.1990.8.1.155. J Clin Oncol. 1990. PMID: 2295906

4

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, et al. Kohn EC, et al. J Natl Cancer Inst. 1994 Jan 5;86(1):18-24. doi: 10.1093/jnci/86.1.18. J Natl Cancer Inst. 1994. PMID: 7505830 Clinical Trial.

5

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy.

Link CJ Jr, Bicher A, Kohn EC, Christian MC, Davis PA, Adamo DO, Reed E, Sarosy GA. Link CJ Jr, et al. Among authors: kohn ec. Blood. 1994 Mar 1;83(5):1188-92. Blood. 1994. PMID: 7509652 Free article. Clinical Trial.

6

Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.

Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M. Reed E, et al. Among authors: kohn ec. Semin Oncol. 1995 Jun;22(3 Suppl 6):90-6. Semin Oncol. 1995. PMID: 7541159 Review.

7

Tumor angiogenesis in advanced stage ovarian carcinoma.

Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Hollingsworth HC, et al. Among authors: kohn ec. Am J Pathol. 1995 Jul;147(1):33-41. Am J Pathol. 1995. PMID: 7541612 Free PMC article.

8

Age does not influence taxol dose intensity in recurrent carcinoma of the ovary.

Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J, Chabner BA, Reed E. Bicher A, et al. Cancer. 1993 Jan 15;71(2 Suppl):594-600. doi: 10.1002/cncr.2820710216. Cancer. 1993. PMID: 7678382 Clinical Trial.

9

The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor.

Bicher A, Kohn E, Sarosy G, Davis P, Adamo DO, Jacob J, Christian M, Reed E. Bicher A, et al. Anticancer Drugs. 1993 Apr;4(2):141-8. doi: 10.1097/00001813-199304000-00003. Anticancer Drugs. 1993. PMID: 7683933

10

Incapacitating autonomic neuropathy precipitated by taxol.

Jerian SM, Sarosy GA, Link CJ Jr, Fingert HJ, Reed E, Kohn EC. Jerian SM, et al. Among authors: kohn ec. Gynecol Oncol. 1993 Nov;51(2):277-80. doi: 10.1006/gyno.1993.1287. Gynecol Oncol. 1993. PMID: 7903950

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

290 results

Search Page

Filters